Fairooz F Kabbinavar

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi request reprint Can inhibition of angiogenic pathways increase the efficacy of intravenous 5-fluorouracil-based regimens?
    Fairooz F Kabbinavar
    Division of Hematology Oncology, Department of Medicine, 10945 Le Conte Ave, University of California Los Angeles 2338 John, PVUB MC, 718707, Los Angeles, CA 90095 7187, USA
    Clin Colorectal Cancer 4:S69-73. 2004
  2. doi request reprint Health-related quality of life impact of bevacizumab when combined with irinotecan, 5-fluorouracil, and leucovorin or 5-fluorouracil and leucovorin for metastatic colorectal cancer
    Fairooz F Kabbinavar
    Division of Hematology Oncology, University of California at Los Angeles, California 90095 7059, USA
    Oncologist 13:1021-9. 2008
  3. doi request reprint Bevacizumab improves the overall and progression-free survival of patients with metastatic colorectal cancer treated with 5-fluorouracil-based regimens irrespective of baseline risk
    Fairooz Kabbinavar
    University of California Los Angeles, Los Angeles, California 90095 7059, USA
    Oncology 75:215-23. 2008
  4. doi request reprint Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials
    Fairooz F Kabbinavar
    Department of Medicine, Division of Hematology and Oncology, University of California at Los Angeles, 2333D PVUB MC 705907, 10945 Le Conte Ave, Los Angeles, CA 90095 7059, USA
    J Clin Oncol 27:199-205. 2009
  5. ncbi request reprint Angiogenesis and angiogenic inhibitors in renal cell carcinoma
    Rishi Sawhney
    Division of Hematology Oncology, David Geffen School of Medicine at UCLA, 10945 LeConte Avenue, Suite 2333D, Box 957059, Los Angeles, CA 90095, USA
    Curr Urol Rep 9:26-33. 2008
  6. ncbi request reprint Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial
    Fairooz F Kabbinavar
    Division of Hematology Oncology, UCLA School of Medicine, 10945 LeConte Ave, Suite 2338J, Los Angeles, CA 90095 7187, USA
    J Clin Oncol 23:3697-705. 2005
  7. ncbi request reprint Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer
    Fairooz Kabbinavar
    Division of Hematology Oncology, University of California Los Angeles, School of Medicine, 90095, USA
    J Clin Oncol 21:60-5. 2003
  8. doi request reprint Clinical, molecular, and genetic correlates of lymphatic spread in clear cell renal cell carcinoma
    Nils Kroeger
    Institute of Urologic Oncology, David Geffen School of Medicine, University of California, Los Angeles, CA, USA
    Eur Urol 61:888-95. 2012
  9. doi request reprint Cancer-specific survival outcomes among patients treated during the cytokine era of kidney cancer (1989-2005): a benchmark for emerging targeted cancer therapies
    Arie S Belldegrun
    Department of Urology, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California 90095 1738, USA
    Cancer 113:2457-63. 2008
  10. doi request reprint Molecular signatures of localized clear cell renal cell carcinoma to predict disease-free survival after nephrectomy
    Tobias Klatte
    Department of Urology, David Geffen School of Medicine, University of California Los Angeles, 10833 Le Conte Avenue, 66 118 CHS, Box 951738, Los Angeles, CA 90095 1738, USA
    Cancer Epidemiol Biomarkers Prev 18:894-900. 2009

Detail Information

Publications49

  1. ncbi request reprint Can inhibition of angiogenic pathways increase the efficacy of intravenous 5-fluorouracil-based regimens?
    Fairooz F Kabbinavar
    Division of Hematology Oncology, Department of Medicine, 10945 Le Conte Ave, University of California Los Angeles 2338 John, PVUB MC, 718707, Los Angeles, CA 90095 7187, USA
    Clin Colorectal Cancer 4:S69-73. 2004
    ..The current study indicates that subpopulations of patients with advanced age or poor performance status could be treated successfully with 5-FU/LV in combination with bevacizumab without excessive toxicities...
  2. doi request reprint Health-related quality of life impact of bevacizumab when combined with irinotecan, 5-fluorouracil, and leucovorin or 5-fluorouracil and leucovorin for metastatic colorectal cancer
    Fairooz F Kabbinavar
    Division of Hematology Oncology, University of California at Los Angeles, California 90095 7059, USA
    Oncologist 13:1021-9. 2008
    ....
  3. doi request reprint Bevacizumab improves the overall and progression-free survival of patients with metastatic colorectal cancer treated with 5-fluorouracil-based regimens irrespective of baseline risk
    Fairooz Kabbinavar
    University of California Los Angeles, Los Angeles, California 90095 7059, USA
    Oncology 75:215-23. 2008
    ..This model was applied to data from phase II/III trials of first-line bevacizumab plus 5-FU/LV with/without irinotecan (IFL)...
  4. doi request reprint Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials
    Fairooz F Kabbinavar
    Department of Medicine, Division of Hematology and Oncology, University of California at Los Angeles, 2333D PVUB MC 705907, 10945 Le Conte Ave, Los Angeles, CA 90095 7059, USA
    J Clin Oncol 27:199-205. 2009
    ....
  5. ncbi request reprint Angiogenesis and angiogenic inhibitors in renal cell carcinoma
    Rishi Sawhney
    Division of Hematology Oncology, David Geffen School of Medicine at UCLA, 10945 LeConte Avenue, Suite 2333D, Box 957059, Los Angeles, CA 90095, USA
    Curr Urol Rep 9:26-33. 2008
    ..This article reviews the role of angiogenesis in RCC and summarizes data regarding antiangiogenic therapy in metastatic RCC...
  6. ncbi request reprint Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial
    Fairooz F Kabbinavar
    Division of Hematology Oncology, UCLA School of Medicine, 10945 LeConte Ave, Suite 2338J, Los Angeles, CA 90095 7187, USA
    J Clin Oncol 23:3697-705. 2005
    ..This randomized, phase II trial compared bevacizumab plus fluorouracil and leucovorin (FU/LV) versus placebo plus FU/LV as first-line therapy in patients considered nonoptimal candidates for first-line irinotecan...
  7. ncbi request reprint Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer
    Fairooz Kabbinavar
    Division of Hematology Oncology, University of California Los Angeles, School of Medicine, 90095, USA
    J Clin Oncol 21:60-5. 2003
    ....
  8. doi request reprint Clinical, molecular, and genetic correlates of lymphatic spread in clear cell renal cell carcinoma
    Nils Kroeger
    Institute of Urologic Oncology, David Geffen School of Medicine, University of California, Los Angeles, CA, USA
    Eur Urol 61:888-95. 2012
    ..While it is well known that clear cell renal cell carcinoma (ccRCC) that presents with lymphatic spread is associated with an extremely poor prognosis, its molecular and genetic biology is poorly understood...
  9. doi request reprint Cancer-specific survival outcomes among patients treated during the cytokine era of kidney cancer (1989-2005): a benchmark for emerging targeted cancer therapies
    Arie S Belldegrun
    Department of Urology, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California 90095 1738, USA
    Cancer 113:2457-63. 2008
    ..The management of renal cell carcinoma (RCC) is evolving toward less extirpative surgery and the use of targeted therapy. The authors set out to provide a benchmark against which emerging therapies should be measured...
  10. doi request reprint Molecular signatures of localized clear cell renal cell carcinoma to predict disease-free survival after nephrectomy
    Tobias Klatte
    Department of Urology, David Geffen School of Medicine, University of California Los Angeles, 10833 Le Conte Avenue, 66 118 CHS, Box 951738, Los Angeles, CA 90095 1738, USA
    Cancer Epidemiol Biomarkers Prev 18:894-900. 2009
    ..To identify the molecular signature of localized (N0M0) clear cell renal cell carcinoma (RCC) and assess its ability to predict outcome...
  11. doi request reprint Deletions of chromosomes 3p and 14q molecularly subclassify clear cell renal cell carcinoma
    Nils Kroeger
    Institute of Urologic Oncology, Department of Urology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA
    Cancer 119:1547-54. 2013
    ..The objective of this study was to evaluate the significance of 3p loss (loss VHL gene) and 14q loss (loss HIF-1α gene) in clear cell renal cell carcinoma (ccRCC)...
  12. ncbi request reprint Metachronous bilateral renal cell carcinoma: risk assessment, prognosis and relevance of the primary-free interval
    Tobias Klatte
    Department of Urology, David Geffen School of Medicine, University of California Los Angeles, 10833 Le Conte Avenue, Los Angeles, CA 90025, USA
    J Urol 177:2081-6; discussion 2086-7. 2007
    ..We evaluated the prognosis, risk factors and relevance of the primary-free interval in a large cohort with metachronous bilateral renal cell carcinoma...
  13. ncbi request reprint Hypoxia-inducible factor 1 alpha in clear cell renal cell carcinoma
    Tobias Klatte
    Department of Urology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA
    Clin Cancer Res 13:7388-93. 2007
    ..Here, we evaluated the significance of HIF-1 alpha in renal cell carcinoma (RCC)...
  14. ncbi request reprint Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer
    Fairooz F Kabbinavar
    University of California Los Angeles, Los Angeles, CA, USA
    J Clin Oncol 23:3706-12. 2005
    ..Three randomized clinical studies have evaluated bevacizumab in combination with FU/LV alone. A combined analysis of raw data from these studies was performed to better assess the efficacy of bevacizumab with FU/LV...
  15. doi request reprint Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm
    Brian Shuch
    Department of Urology, David Geffen School of Medicine, University of California Los Angeles, CA 90095, USA
    BJU Int 102:692-6. 2008
    ....
  16. doi request reprint CA9 gene: single nucleotide polymorphism predicts metastatic renal cell carcinoma prognosis
    Michela de Martino
    Department of Urology, University of California Los Angeles, Los Angeles, California 90095 1738, USA
    J Urol 182:728-34. 2009
    ..The CA9 gene exons and flanking regions were amplified by polymerase chain reaction and sequenced. The monoclonal antibody M75 was used to evaluate CAIX protein expression in the primary tumor by immunohistochemistry...
  17. doi request reprint Smoking negatively impacts renal cell carcinoma overall and cancer-specific survival
    Nils Kroeger
    Institute of Urologic Oncology, David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, California 90095 7207, USA
    Cancer 118:1795-802. 2012
    ..The authors of this report retrospectively studied the impact of smoking on clinicopathologic factors, survival outcomes, and p53 expression status in a large cohort of patients with RCC...
  18. doi request reprint Presence of tumor necrosis is not a significant predictor of survival in clear cell renal cell carcinoma: higher prognostic accuracy of extent based rather than presence/absence classification
    Tobias Klatte
    Department of Urology, University of California Los Angeles, Los Angeles, California, USA
    J Urol 181:1558-64; discussion 1563-4. 2009
    ..We performed the first prospective study of necrosis in clear cell renal cell carcinoma to our knowledge and tested the traditional presence/absence classification vs an alternative extent based classification...
  19. doi request reprint Pathobiology and prognosis of chromophobe renal cell carcinoma
    Tobias Klatte
    Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
    Urol Oncol 26:604-9. 2008
    ..To analyze pathobiology and prognosis of chromophobe renal cell carcinoma (CRCC)...
  20. doi request reprint Pathological, immunohistochemical and cytogenetic features of papillary renal cell carcinoma with clear cell features
    Tobias Klatte
    Department of Urology, University of California Los Angeles, Los Angeles, California, USA
    J Urol 185:30-5. 2011
    ..Typically the cells have a chromophilic appearance but areas may show cells with clear cytoplasm, similar to those in clear cell renal cell carcinoma...
  21. ncbi request reprint The chemokine receptor CXCR3 is an independent prognostic factor in patients with localized clear cell renal cell carcinoma
    Tobias Klatte
    Department of Urology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California 90095 1738, USA
    J Urol 179:61-6. 2008
    ..To evaluate its role in the biology of clear cell renal cell carcinoma we performed a tissue microarray based study...
  22. pmc Histologic evaluation of metastases in renal cell carcinoma with sarcomatoid transformation and its implications for systemic therapy
    Brian Shuch
    Department of Urology, David Geffen School of Medicine at University of California Los Angles, Los Angeles, California 90095 1738, USA
    Cancer 116:616-24. 2010
    ..The patterns of metastases for these tumors were evaluated to determine if sarcomatoid features were retained at metastasis and whether the percentage of sarcomatoid features in the primary tumor influenced spread...
  23. doi request reprint Cytogenetic and molecular tumor profiling for type 1 and type 2 papillary renal cell carcinoma
    Tobias Klatte
    Department of Urology, University of California at Los Angeles School of Medicine, Los Angeles, California 90095 1738, USA
    Clin Cancer Res 15:1162-9. 2009
    ..The goal of this study was to evaluate immunohistochemical and cytogenetic features and their prognostic value in papillary renal cell carcinoma (PRCC) subtypes...
  24. doi request reprint Cytogenetic profile predicts prognosis of patients with clear cell renal cell carcinoma
    Tobias Klatte
    Department of Urology, David Geffen School of Medicine at UCLA, Center for Health Sciences, Los Angeles, CA 90025 1738, USA
    J Clin Oncol 27:746-53. 2009
    ..We prospectively studied the prognostic impact of cytogenetic abnormalities on a larger cohort of patients having up to 108 months of follow-up...
  25. ncbi request reprint Prognostic impact of tumor size on pT2 renal cell carcinoma: an international multicenter experience
    Tobias Klatte
    Department of Urology, University of California, Los Angeles, Los Angeles, California 90095 1738, USA, and Centre Hospitalier Universitaire Pontchaillou, Rennes, France
    J Urol 178:35-40; discussion 40. 2007
    ..We examined the current pT2 tumor classification of renal cell carcinoma and determined whether a tumor size cutoff exists that would improve prognostic accuracy...
  26. doi request reprint Brain metastasis from renal cell carcinoma: presentation, recurrence, and survival
    Brian Shuch
    Department of Urology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California 90095 1738, USA
    Cancer 113:1641-8. 2008
    ..The objective of the current study was to assist in the creation of treatment guidelines...
  27. doi request reprint Salvage-targeted kidney cancer therapy in patients progressing on high-dose interleukin-2 immunotherapy: the UCLA experience
    Frédéric D Birkhäuser
    Institute of Urologic Oncology, David Geffen School of Medicine, University of California, Los Angeles, CA 90024, USA
    Cancer J 19:189-96. 2013
    ..To analyze the outcomes of patients with metastatic renal cell carcinoma treated with salvage-targeted therapy after progressing on high-dose interleukin (IL)-2 immunotherapy in a tertiary referral center...
  28. ncbi request reprint Prognostic factors for renal cell carcinoma with tumor thrombus extension
    Tobias Klatte
    Department of Urology, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California 90095 1738, USA
    J Urol 178:1189-95; discussion 1195. 2007
    ..We identified prognostic factors for renal cell carcinoma with tumor thrombus extension and assessed whether the current T3 classification could be improved...
  29. doi request reprint Fuhrman grade provides higher prognostic accuracy than nucleolar grade for papillary renal cell carcinoma
    Tobias Klatte
    Department of Urology, University of California Los Angeles, Los Angeles, California 90025 1738, USA
    J Urol 183:2143-7. 2010
    ..Recent evidence suggests that nucleolar grade but not Fuhrman grade is applicable to papillary renal cell carcinoma. We tested this hypothesis in an independent large series from a single institution...
  30. doi request reprint Gain of chromosome 8q is associated with metastases and poor survival of patients with clear cell renal cell carcinoma
    Tobias Klatte
    Department of Urology, Institute of Urologic Oncology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California 90095 7384, USA
    Cancer 118:5777-82. 2012
    ..The aim of this study was to evaluate the prevalence of chromosome 8q gain in clear cell renal cell carcinoma (CCRCC) and to correlate the findings with tumor phenotype and disease-specific survival (DSS)...
  31. doi request reprint Tumor size does not predict risk of metastatic disease or prognosis of small renal cell carcinomas
    Tobias Klatte
    Department of Urology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California 90025 1738, USA
    J Urol 179:1719-26. 2008
    ..We characterized the clinicopathological features and the prognosis of small solid renal tumors defined as tumors 4 cm or smaller...
  32. doi request reprint Gastrointestinal perforation associated with bevacizumab use in metastatic colorectal cancer: results from a large treatment observational cohort study
    Fairooz F Kabbinavar
    Department of Medicine, Division of Hematology and Oncology, University of California at Los Angeles, 924 Westwood Blvd, Los Angeles, CA 90095 7207, USA
    Eur J Cancer 48:1126-32. 2012
    ..We sought to describe the incidence, temporal pattern, outcomes and potential risk factors for GIP in a large, community-based observational cohort study of patients treated with bevacizumab...
  33. doi request reprint Dendritic cell-based immunotherapy in prevention and treatment of renal cell carcinoma: efficacy, safety, and activity of Ad-GM·CAIX in immunocompetent mouse models
    Frédéric D Birkhäuser
    Institute of Urologic Oncology, David Geffen School of Medicine at the University of California, Los Angeles, CA 90024, USA
    J Immunother 36:102-11. 2013
    ....
  34. doi request reprint Prognostic value of microvascular invasion in predicting the cancer specific survival and risk of metastatic disease in renal cell carcinoma: a multicenter investigation
    Nils Kroeger
    UCLA Institute of Urologic Oncology, David Geffen School of Medicine, Los Angeles, CA, USA
    J Urol 187:418-23. 2012
    ..Therefore, a large multicenter study examining the experience of 5 international institutions was performed to evaluate the prognostic value of microvascular invasion in the occurrence of metastases and cancer specific survival...
  35. doi request reprint The chromophobe tumor grading system is the preferred grading scheme for chromophobe renal cell carcinoma
    David S Finley
    Institute of Urologic Oncology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California 90095, USA
    J Urol 186:2168-74. 2011
    ..We compared the 2 scoring systems in a large sporadic chromophobe renal cell carcinoma cohort to determine which grading scheme provides the most predictive assessment of clinical risk...
  36. doi request reprint Performance status and cytoreductive nephrectomy: redefining management in patients with poor performance
    Brian Shuch
    Department of Urology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California 90095 1738, USA
    Cancer 113:1324-31. 2008
    ..The objective of the current study was to investigate the outcomes of cytoreductive nephrectomy (CN) for patients who have an impaired performance status (ECOG PS 2/3)...
  37. doi request reprint Functional and oncological outcomes of partial nephrectomy of solitary kidneys
    Jeffrey La Rochelle
    Department of Urology, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California, USA
    J Urol 181:2037-42; discussion 2043. 2009
    ....
  38. pmc Systemic therapy for metastatic renal cell carcinoma: a review and update
    Joshua E Logan
    Institute of Urologic Oncology, Department of Urology, The David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA
    Rev Urol 14:65-78. 2012
    ..And finally, management of metastatic non-clear cell RCC histologies are discussed focusing on available evidence to direct decision making when assessing therapeutic options...
  39. ncbi request reprint Overexpression of AKT2/protein kinase Bbeta leads to up-regulation of beta1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cells
    M Jane Arboleda
    Department of Medicine, Division of Hematology and Oncology, University of California Los Angeles, UCLA School of Medicine, Los Angeles, California 90095, USA
    Cancer Res 63:196-206. 2003
    ..Taken together, these data indicate that AKT2 mediates PI3-K-dependent effects on adhesion, motility, invasion, and metastasis in vivo...
  40. ncbi request reprint Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen
    Timothy F Cloughesy
    Henry Singleton Brain Cancer Research Program, UCLA School of Medicine, Los Angeles, California 90095, USA
    Cancer 97:2381-6. 2003
    ..A higher level of efficacy for CPT-11 may be observed if an MTD can efficiently be established for each patient...
  41. doi request reprint A phase II trial of docetaxel with bevacizumab as first-line therapy for HER2-negative metastatic breast cancer (TORI B01)
    Sara A Hurvitz
    David Geffen School of Medicine, University of California, Los Angeles, CA, USA
    Clin Breast Cancer 10:307-12. 2010
    ..To assess the activity of docetaxel plus bevacizumab, a multicenter phase II trial was conducted...
  42. ncbi request reprint A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period
    Carolyn D Britten
    David Geffen School of Medicine at the University of California, Los Angeles 90095, USA
    Cancer Chemother Pharmacol 61:515-24. 2008
    ..This trial was performed to investigate the safety, tolerability, and pharmacokinetics of sunitinib 50 mg daily for 2 weeks followed by a 1-week off period (2/1 schedule)...
  43. ncbi request reprint Irinotecan treatment for recurrent malignant glioma using an every-3-week regimen
    Timothy F Cloughesy
    UCLA School of Medicine, Henry Singleton Brain Cancer Research Program, Los Angeles, California, USA
    Am J Clin Oncol 25:204-8. 2002
    ..The concurrent use of anticonvulsant medications may have played a role in altering pharmacokinetics and thus the maximum tolerated dose in this patient population...
  44. ncbi request reprint Clinicopathological features and prognosis of synchronous bilateral renal cell carcinoma: an international multicentre experience
    Tobias Klatte
    Department of Urology, David Geffen School of Medicine at UCLA, University of California Los Angeles, 10833 Le Conte Avenue, Los Angeles, CA 90025, USA
    BJU Int 100:21-5. 2007
    ..To present a multicentre experience and the largest cohort to date of nonmetastatic (N0M0) synchronous bilateral renal cell carcinoma (RCC), as because it is rare the single-institutional experience is limited...
  45. ncbi request reprint Multicenter Phase II study of estramustine phosphate plus weekly paclitaxel in patients with androgen-independent prostate carcinoma
    David J Vaughn
    Department of Medicine, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    Cancer 100:746-50. 2004
    ..The current study determined the efficacy and toxicity of weekly paclitaxel in combination with estramustine phosphate (EMP) in patients with androgen-independent prostate carcinoma (AIPC)...
  46. ncbi request reprint Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer
    David H Johnson
    Division of Hematology and Oncology, Vanderbilt University Medical School, 777 Preston Research Bldg, Nashville, TN, USA
    J Clin Oncol 22:2184-91. 2004
    ..To investigate the efficacy and safety of bevacizumab plus carboplatin and paclitaxel in patients with advanced or recurrent non-small-cell lung cancer...
  47. doi request reprint Chromosome 9p deletions identify an aggressive phenotype of clear cell renal cell carcinoma
    Jeffrey La Rochelle
    Department of Urology, David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, California 90025, USA
    Cancer 116:4696-702. 2010
    ....
  48. ncbi request reprint Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer
    Ronald M Bukowski
    Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    J Clin Oncol 25:4536-41. 2007
    ....
  49. ncbi request reprint Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium
    Christopher J Sweeney
    Hoosier Oncology Group, Indianapolis, IN, USA
    J Clin Oncol 24:3451-7. 2006
    ..To assess the antitumor activity and toxicity of pemetrexed as second-line chemotherapy in patients with locally advanced or metastatic transitional cell carcinoma (TCC) of the urothelium...